Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | RARA | P10276 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 1/20 | 0.42 |
| ▸ | RARG | P13631 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5217933 | 0.85 | HPGD (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9256029 | 0.78 | CTSS (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5217488 | 0.78 | HPGD (0.45) | HPGDALDH1A1KDM4EHSD17B10CYP1A2 | |
| SCHEMBL17472765 | 0.75 | CA12 (0.40) | CA12CA1CA2CA7CA9 | |
| SCHEMBL24595883 | 0.74 | NPC1 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2997892 | 0.73 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31329022 | 0.72 | SIRT2 (0.46) | CA12CA9HPGDALDH1A1KDM4E | |
| SCHEMBL6053686 | 0.72 | CA12 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28609425 | 0.72 | RAB9A (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18049247 | 0.72 | JMJD6 (0.46) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368318-B1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-12-05 | — | — | EP | disclosed |
| US-6864267-B2 | Calcilytic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-08 | — | — | US | disclosed |
| EP-1368318-A2 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20030212110-A1 | Glandular disorders; bone disorders | SMITHKLINE BEECHAM CORPORATION | 2003-11-13 | — | — | US | disclosed |
| WO-2002007673-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212110-A1 | Glandular disorders; bone disorders | CYP24A1, PTH1R, SOST | CA12 110/4885CA1 191/4885CA2 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.